Nuvectis Pharma (NVCT) Net Income towards Common Stockholders (2021 - 2026)
Nuvectis Pharma (NVCT) posted Net Income towards Common Stockholders of -$6.0 million for Q1 2026, up 17.28% sequentially from -$7.3 million in Q4 2025, and down 13.47% YoY from -$7.0 million in Q1 2025.
Nuvectis Pharma (NVCT) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$6.0 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 13.47% year-over-year to -$6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.6 million (down 46.76% YoY) and the FY2025 annual result came in at -$28.9 million, down 51.95% from the prior year.
- Net Income towards Common Stockholders improved to -$6.0 million in Q1 2026 per NVCT's latest filing, from -$7.3 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$2.9 million in Q1 2022 and troughed at -$9.9 million in Q3 2025.
- A 5-year average of -$5.6 million and a median of -$5.9 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The widest YoY moves for Net Income towards Common Stockholders: up 39.9% in 2022, down 196.15% in 2022.
- Over 5 years, Net Income towards Common Stockholders stood at -$6.7 million in 2022, then climbed by 1.11% to -$6.6 million in 2023, then rose by 5.65% to -$6.2 million in 2024, then dropped by 17.06% to -$7.3 million in 2025, then gained by 17.28% to -$6.0 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$6.0 million, -$7.3 million, and -$9.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | -7.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.02 Mn |
| Mar 31, 2026 | -6.05 Mn |
| Dec 31, 2025 | -7.31 Mn |
| Sep 30, 2025 | -9.89 Mn |
| Jun 30, 2025 | -6.33 Mn |
| Mar 31, 2025 | -5.33 Mn |
| Dec 31, 2024 | -6.25 Mn |
| Sep 30, 2024 | -4.15 Mn |
| Jun 30, 2024 | -4.43 Mn |
| Mar 31, 2024 | -4.17 Mn |
| Dec 31, 2023 | -6.62 Mn |
| Sep 30, 2023 | -5.88 Mn |
| Jun 30, 2023 | -5.71 Mn |
| Mar 31, 2023 | -4.05 Mn |
| Dec 31, 2022 | -6.70 Mn |
| Sep 30, 2022 | -5.88 Mn |
| Jun 30, 2022 | -3.57 Mn |
| Mar 31, 2022 | -2.94 Mn |
| Dec 31, 2021 | -2.26 Mn |
| Sep 30, 2021 | -4.67 Mn |